Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
crispr
3
×
editas medicine
biotech
boston blog main
boston top stories
gene editing
government
katrine bosley
life sciences
national blog main
advaxis
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
allergan
andrew oxtoby
babies
bill gates
bio
boston
boulder/denver blog main
boulder/denver top stories
breakup
bridge bio pharma
ceo
clinical hold
clinical study
clinical trials
combination
commissioner
congress
crispr-cas9
cynthia collins
delisting
democrats
departure
detroit blog main
detroit top stories
drug pricing
drugs
What
crispr
3
×
editas
3
×
ceo
editing
gene
katrine
medicine
allergan
believe
big
bio
biotech
blessing
bosley
bosley's
bosley’s
bridge
bucks
built
cas
check
clinical
company’s
concerns
crime
cusp
debut
depart
departure
dispute
drop
drops
exit
experimental
far
guiding
hours
humans
ipo’s
legally
Language
Current search:
crispr
×
crispr
×
editas
×
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@techcrunch.com
8 years ago
Editas biotech stock drops by 26% over CRISPR patent dispute